Tolmar Establishes Tolmar Canada to Sell, Market and Distribute ELIGARD® in Canada
Retrieved on:
Friday, October 8, 2021
Man, Pain, Fatigue, Testosterone, History, Myalgia, Risk, Hypersensitivity, Gynecomastia, Dizziness, Convulsion, Food, Prostate cancer, Bone density, Pituitary apoplexy, Gonadotropin-releasing hormone, Hyperglycemia, Bruise, Marketing, Anaphylaxis, Fertility, Erythema, Peripheral neuropathy, Literature, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Serum, IL, Bone pain, Stroke, Weakness, Hematuria, CEO, Myocardial infarction, Spinal cord compression, Testicular atrophy, Patient, Cardiovascular disease, QT, Pharmaceutical industry
BUFFALO GROVE, Ill., Oct. 8, 2021 /PRNewswire/ -- Tolmar, a specialty pharmaceutical company, today announced that, effective January 1, 2022, the company will hold exclusive distribution rights to ELIGARD® (leuprolide acetate for injectable suspension) in Canada. ELIGARD® is a prescription medication for the palliative treatment of advanced prostate cancer.
Key Points:
- With the establishment of Tolmar Pharmaceuticals Canada, Tolmar will resume the rights to ELIGARD in the Canadian market.
- Tolmar will exclusively market, sell, and distribute ELIGARD in Canada after those respective dates.
- "We are excited to regain the sales and marketing rights for ELIGARDin Canada," said Anil D'souza, CEO of Tolmar Pharmaceuticals.
- The establishment of Tolmar Pharmaceuticals Canada will allow Tolmar to continue to advance ELIGARDinto the future."